ACBM — Acro Biomedical Co Income Statement
0.000.00%
Last trade - 00:00Consumer DefensivesSpeculativeMicro Cap
Annual income statement for Acro Biomedical Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.688 | 1.2 | 0.658 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.159 | 0.26 | 0.141 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.818 | 8.89 | 16.5 | 8.8 | 0.038 |
| Operating Profit | -0.13 | -7.69 | -15.9 | -8.8 | -0.038 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.136 | -7.7 | -15.9 | -8.81 | -0.042 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.117 | -7.7 | -15.9 | -8.81 | -0.042 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.117 | -7.7 | -15.9 | -8.81 | -0.042 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.117 | -7.7 | -15.9 | -8.81 | -0.042 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.143 | -0.264 | -0.147 | -0.001 |